On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.

On the news front, China's National Healthcare Security Administration published the initial review results for the 2026 basic medical insurance directory and commercial insurance innovative drug directory, with 557 drugs passing the medical insurance directory review and 54 drugs passing the commercial insurance directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining public and commercial insurance. CITIC Construction Investment noted optimism for innovative drug enterprises' insurance access and incremental commercial insurance opportunities.

On the company level, all indications of Akeso's five self-developed drugs have been included in national medical insurance, while its new drug Qiyoukang has completed its first nationwide delivery, expected to accelerate market penetration. The broader biotech sector rallied in tandem, with 3SBio up 6.78%, Remegen up 6.87%, SKB Bio up 6.5%, and BeiGene up 4.81%, reflecting strong sector beta momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)